Edition:
United States

Alere Inc (ALR_pb.N)

ALR_pb.N on New York Stock Exchange

332.00USD
28 Sep 2016
Change (% chg)

$-8.03 (-2.36%)
Prev Close
$343.03
Open
$332.00
Day's High
$332.00
Day's Low
$332.00
Volume
100
Avg. Vol
628
52-wk High
$406.88
52-wk Low
$255.75

Latest Key Developments (Source: Significant Developments)

Pharos Capital acquires TechLab
Monday, 19 Sep 2016 07:30am EDT 

Pharos Capital Group : Pharos Capital acquires TechLab, leading developer of gastrointestinal disease diagnostics .Acquiring its stake from Alere, TechLab's founders Tracy Wilkins and David Lyerly.  Full Article

Alere Q2 loss per share $0.46 from continuing operations
Tuesday, 6 Sep 2016 07:00am EDT 

Alere Says With Filing Of Q2 2016 Form 10 : Alere reports second quarter 2016 financial results . Q2 revenue $611 million versus I/B/E/S view $607.4 million . Q2 loss per share $0.46 from continuing operations . Q2 earnings per share view $0.58 -- Thomson Reuters I/B/E/S .Alere says with filing of Q2 2016 form 10-Q now current in financial filings and are on track to report our Q3 2016 results within normal time frame.  Full Article

Abbott Laboratories says "Alere’s lawsuit is without merit"
Friday, 26 Aug 2016 12:26pm EDT 

Abbott Laboratories : Abbott Laboratories says "Alere’s lawsuit is without merit" . Compliant with obligations under merger agreement with Alere . "continues to work toward regulatory approvals despite Alere’s nearly six month delay in filing its 2015 10-K" ((Bangalore.newsroom@thomsonreuters.com ;)).  Full Article

Alere says filed a complaint against Abbott on Aug. 25
Friday, 26 Aug 2016 11:00am EDT 

Alere Inc : Alere issues statement . "on August 25, 2016, Alere filed a complaint against Abbott in Delaware Chancery court" . Says expect redacted version of complaint to be publicly available next week . Expect redacted version of complaint to be publicly available next week .Alere will "compel" Abbott to complete transaction in accordance with its terms.  Full Article

Alere gets FDA clearance for its RSV rapid molecular test
Friday, 19 Aug 2016 07:00am EDT 

Alere Inc : Alere receives FDA clearance for Alere™ I RSV rapid molecular test . Alere will shortly submit an application for clia waiver of Alere I RSV test .Alere I testing applications have previously been clia-waived for Influenza a & b and strep a.  Full Article

Alere entered into a second amendment to secured credit agreement
Thursday, 18 Aug 2016 05:13pm EDT 

Alere Inc : On August 18 entered into a second amendment to secured credit agreement .Second amendment extends the deadline for delivery of the Q2 financial reports to September 13, 2016 - sec filing.  Full Article

Alere Q1 loss per share $0.18 from continuing operations
Wednesday, 17 Aug 2016 06:15am EDT 

Alere Inc : Q1 earnings per share view $0.56, revenue view $602.6 million -- Thomson Reuters I/B/E/S . Based on current business outlook, expect improved organic revenue growth in q2 and second half of 2016 . Amendment to secured credit agreement to provide extension of date by co will file q2 financial statements under secured credit agreement to sept 13 . Currently plans to file q2 form 10-q by sept 13, 2016, expects to pay about $3 million in fees to obtain amendment to secured credit amendment . Revenue for q1 of 2016 was $578 million, a 6% decrease compared to $613 million in prior year period .Company is seeking an amendment to its secured credit agreement.  Full Article

Alere achieves IVD CE mark for Alere reader lateral flow assay analyzer
Tuesday, 9 Aug 2016 07:00am EDT 

Alere Inc : Alere achieves IVD CE mark for its Alere™ reader lateral flow assay analyzer .Alere reader will launch initially in Europe, with other regions to follow.  Full Article

Alere reports Q4 loss per share $0.28 from continuing operations
Monday, 8 Aug 2016 06:22am EDT 

Alere : Files Form 10-K, reports fourth quarter and full year 2015 financial results . Q4 revenue $623 million versus I/B/E/S view $628.5 million . Q4 loss per share $0.28 from continuing operations . Q4 earnings per share view $0.58 -- Thomson Reuters I/B/E/S . Concluded analysis of certain aspects of revenue recognition for years ended december 31, 2015, 2014, and 2013 . Does not currently expect to file its Q2 2016 form 10-Q by August 9, 2016 . Expects to file its Q2 2016 form 10-Q "as soon as practicable" . Recognized additional income tax expense of $8 million in 2015 (nine months ytd) and a reduction in income tax expense of $7 million in 2014 . Tax-Related revisions resulted in an increase of $0.07 in basic and diluted earnings per share in 2014 . Has revised its financial statements for interim periods of 2015 and years ended december 31, 2014 and 2013 to correct immaterial errors . Alere expects to file its q1 2016 form 10-q by August 18, 2016 . "In the process of implementing a remediation plan and remain committed to providing accurate and transparent financial reporting" . The tax-related revisions resulted in a decrease of $0.09 in basic and diluted earnings per share in 2015 .None of these financial statement revisions impacted company's cash flow or cash balances.  Full Article

Alere opens new diagnostics manufacturing facility in India
Monday, 1 Aug 2016 04:15pm EDT 

Alere Inc : Alere opens new diagnostics manufacturing facility in India . Manesar facility will initially produce approximately 150 million rapid diagnostic tests annually .Manesar facility will have capacity to double production to more than 300 million tests over time.  Full Article

Abbott, Alere agree to mediate merger dispute

Medical device maker Abbott Laboratories and Alere Inc agreed on Thursday to work with a mediator to settle their dispute over Abbott's role in obtaining U.S. antitrust clearance for its $5.8 billion takeover of the diagnostics company, but Alere voiced concern about the speed of the process.